{"id":"influenza-fluzone-vaccine","safety":{"commonSideEffects":[{"rate":"10–40","effect":"Injection site soreness, redness, or swelling"},{"rate":"5–15","effect":"Myalgia (muscle aches)"},{"rate":"5–15","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) influenza virus particles or recombinant viral antigens that trigger both humoral and cellular immune responses. Upon vaccination, B cells produce strain-specific antibodies that neutralize circulating influenza viruses, while T cells develop memory responses to provide broader protection. This prevents or reduces the severity of influenza infection when vaccinated individuals encounter wild-type virus.","oneSentence":"Fluzone is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against circulating influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:51.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza A and B in adults and children ≥6 months of age"}]},"trialDetails":[{"nctId":"NCT06417853","phase":"PHASE1","title":"Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)","status":"COMPLETED","sponsor":"Vaxxas Pty Ltd","startDate":"2024-07-31","conditions":"H7N9 Influenza","enrollment":267},{"nctId":"NCT07496450","phase":"PHASE3","title":"A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT04304768","phase":"PHASE4","title":"Opioid, HIV and Immune System","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-11-18","conditions":"Immune Defect","enrollment":400},{"nctId":"NCT01386424","phase":"","title":"Screening for LID Clinical Studies Unit Healthy Volunteer Protocols","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-07-20","conditions":"Zika, Influenza","enrollment":5000},{"nctId":"NCT07204964","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-07","conditions":"Influenza, Human","enrollment":971},{"nctId":"NCT07215858","phase":"PHASE2","title":"BPL-1357 Against H1N1 Influenza Virus Challenge","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza, Human","enrollment":129},{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT05921448","phase":"EARLY_PHASE1","title":"Vaccine Pandemic Preparedness Through Airway Immunology Characterization","status":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2025-05-19","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT07493460","phase":"PHASE4","title":"Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-08-26","conditions":"Immunology, Healthy Adults","enrollment":25},{"nctId":"NCT04381689","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-10-23","conditions":"Healthy","enrollment":245},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT07300085","phase":"PHASE1","title":"A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cidara Therapeutics Inc.","startDate":"2025-11-08","conditions":"Healthy Participants","enrollment":100},{"nctId":"NCT01191853","phase":"","title":"Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-09-18","conditions":"Healthy Volunteers, Influenza","enrollment":203},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT07128615","phase":"PHASE1, PHASE2","title":"A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-04","conditions":"Influenza A","enrollment":405},{"nctId":"NCT07431853","phase":"PHASE2","title":"A Study to Learn About mRNA Vaccines Against Influenza in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-23","conditions":"Healthy Adults","enrollment":770},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT07340047","phase":"PHASE1","title":"H1ssF Flu Vaccine Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-08-01","conditions":"Influenza","enrollment":112},{"nctId":"NCT06489964","phase":"NA","title":"Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-23","conditions":"Preventable Disease, Vaccine","enrollment":600},{"nctId":"NCT04579588","phase":"","title":"Understanding Immunity to the Flu Vaccine in COVID-19 Patients","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-10-29","conditions":"Corona Virus Infection, Flu Vaccine, Immunity","enrollment":230},{"nctId":"NCT02140047","phase":"PHASE2","title":"Exploratory Clinical Study of MT-2301","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-04","conditions":"Haemophilus Influenza Type b","enrollment":154},{"nctId":"NCT05705440","phase":"PHASE3","title":"A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-02-07","conditions":"Respiratory Syncytial Virus Infections","enrollment":3855},{"nctId":"NCT02200276","phase":"NA","title":"Influenza Immunization in Adults Over Age 75","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2014-03","conditions":"Influenza, Immunization, Older Adults","enrollment":1025},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT07291635","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine","status":"RECRUITING","sponsor":"Aramis Biotechnologies Inc.","startDate":"2026-02-25","conditions":"Influenza","enrollment":728},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06848309","phase":"","title":"Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host","enrollment":300},{"nctId":"NCT06229392","phase":"PHASE1","title":"A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2026-06-01","conditions":"Breast Cancer, Breast Cancer Triple Negative","enrollment":""},{"nctId":"NCT07460154","phase":"NA","title":"Structured Review: To Optimise Management and Prevent Harm in COPD","status":"NOT_YET_RECRUITING","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2026-03-01","conditions":"COPD","enrollment":96},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT05446740","phase":"PHASE1","title":"A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-08-09","conditions":"Influenza, Human","enrollment":324},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT06336317","phase":"PHASE4","title":"Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-24","conditions":"Acute Myocardial Infarction, Cardiovascular Diseases, Inflammatory Response","enrollment":90},{"nctId":"NCT06676644","phase":"NA","title":"Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Influenza Vaccines, Elderly","enrollment":200},{"nctId":"NCT06179446","phase":"PHASE1","title":"A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-13","conditions":"Grippe, Influenza, Vaccines","enrollment":157},{"nctId":"NCT06863142","phase":"PHASE1","title":"Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-28","conditions":"Influenza Prevention, Seasonal Influenza","enrollment":45},{"nctId":"NCT04164212","phase":"PHASE4","title":"Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-09-01","conditions":"Influenza","enrollment":33},{"nctId":"NCT07421050","phase":"PHASE1","title":"Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-11-13","conditions":"Influenza, Influenza Vaccine","enrollment":80},{"nctId":"NCT07421037","phase":"PHASE1","title":"Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-11-13","conditions":"Influenza, Influenza Vaccine","enrollment":80},{"nctId":"NCT01086904","phase":"PHASE2","title":"Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Renal Transplant Recipients, Immunosuppression","enrollment":122},{"nctId":"NCT06567860","phase":"PHASE4","title":"Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations","status":"COMPLETED","sponsor":"La Jolla Institute for Immunology","startDate":"2024-05-21","conditions":"Influenza A","enrollment":23},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT07161739","phase":"NA","title":"Vaccination Nudges From Pharmacists","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2025-11-06","conditions":"Stroke, Influenza Human, Influenza Vaccines","enrollment":20000},{"nctId":"NCT07282795","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-03-31","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":670},{"nctId":"NCT05108818","phase":"PHASE4","title":"Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-10-07","conditions":"Influenza, Human","enrollment":700},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06382311","phase":"PHASE1, PHASE2","title":"A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-18","conditions":"Influenza, Human","enrollment":991},{"nctId":"NCT07386509","phase":"EARLY_PHASE1","title":"WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-03-17","conditions":"Healthy","enrollment":2},{"nctId":"NCT07019883","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-06-12","conditions":"Avian Influenza","enrollment":80},{"nctId":"NCT06602531","phase":"PHASE1","title":"Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-12-10","conditions":"Influenza, Human","enrollment":212},{"nctId":"NCT07372950","phase":"NA","title":"Kaiser Colorado Flu Nudge","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaiser Permanente","startDate":"2025-10-06","conditions":"Influenza, Vaccination","enrollment":100000},{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT07310472","phase":"NA","title":"Administration of the Nasal Influenza Vaccine to Children in Daycare or at a Healthcare Facility","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2025-10-27","conditions":"Influenza Vaccination","enrollment":6000},{"nctId":"NCT02597647","phase":"PHASE1","title":"Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-02","conditions":"Influenza","enrollment":17},{"nctId":"NCT07111078","phase":"PHASE1","title":"Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-08-27","conditions":"Influenza Prevention, Pandemic Influenza Prevention","enrollment":56},{"nctId":"NCT06074237","phase":"NA","title":"Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters","status":"COMPLETED","sponsor":"Corewell Health East","startDate":"2024-04-25","conditions":"Vaccine Refusal, Vaccine-Preventable Diseases, Physician-Patient Relations","enrollment":112},{"nctId":"NCT07357467","phase":"","title":"Effect of Oral Supplement on Influenza Vaccine Long-term Response","status":"NOT_YET_RECRUITING","sponsor":"Tsinghua University","startDate":"2026-03","conditions":"Influenza, Immunosenescence","enrollment":30},{"nctId":"NCT06727058","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-09","conditions":"Influenza Immunization","enrollment":276},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT07275060","phase":"PHASE4","title":"Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-14","conditions":"H5N1 Influenza, H5N1 Virus, Avian Influenza","enrollment":312},{"nctId":"NCT07349017","phase":"PHASE1","title":"A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-02-07","conditions":"Influenza","enrollment":160},{"nctId":"NCT06907511","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-04-17","conditions":"Pandemic Influenza Immunization, Healthy Volunteers","enrollment":720},{"nctId":"NCT07327398","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2026-01-07","conditions":"Influenza","enrollment":1200},{"nctId":"NCT06503900","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-12","conditions":"Birth Outcomes, Safety, Adverse Event Following Immunization","enrollment":98},{"nctId":"NCT07302256","phase":"PHASE1","title":"A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-12-16","conditions":"Influenza","enrollment":120},{"nctId":"NCT05160636","phase":"","title":"A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-01-31","conditions":"COVID-19, Coronavirus Disease 2019, Influenza","enrollment":999},{"nctId":"NCT06024096","phase":"PHASE4","title":"Systems Biological Assessment of Statin Effect on Vaccine Responses","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-09-20","conditions":"Vaccine Response","enrollment":63},{"nctId":"NCT07259252","phase":"NA","title":"Influenza Vaccination After Acute Coronary Syndrome","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-03","conditions":"Acute Coronary Syndromes (ACS)","enrollment":6620},{"nctId":"NCT01901770","phase":"NA","title":"The Parents in Appalachia Receive Education Needed for Teen Project","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2012-01","conditions":"Healthy, Human Papilloma Virus Infection","enrollment":624},{"nctId":"NCT05384288","phase":"","title":"Response to Influenza Vaccination in Pediatric Oncology Patients","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-10-07","conditions":"Hematologic Malignancy, Pediatric Cancer, Transplant-Related Cancer","enrollment":150},{"nctId":"NCT07332689","phase":"","title":"Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-10-30","conditions":"Influenza Vaccine","enrollment":42881},{"nctId":"NCT06560151","phase":"PHASE2","title":"Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2024-08-21","conditions":"Influenza","enrollment":1380},{"nctId":"NCT06436703","phase":"PHASE2","title":"A Study About Modified RNA Vaccines Against Influenza in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":1202},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT02992925","phase":"PHASE3","title":"Phase 3 Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-11","conditions":"Immunization; Infection","enrollment":370},{"nctId":"NCT05968989","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-08-09","conditions":"Influenza","enrollment":30},{"nctId":"NCT03891758","phase":"PHASE3","title":"Confirmatory Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-01","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":267},{"nctId":"NCT03188692","phase":"PHASE3","title":"Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-06-23","conditions":"Immunization","enrollment":33},{"nctId":"NCT05645900","phase":"PHASE3","title":"A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-02-06","conditions":"Influenza","enrollment":2772},{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT06824779","phase":"PHASE4","title":"Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2025-12-05","conditions":"Volunteers, Flu Vaccine","enrollment":30},{"nctId":"NCT07305207","phase":"PHASE1","title":"Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness","status":"NOT_YET_RECRUITING","sponsor":"Dalhousie University","startDate":"2026-02-01","conditions":"Influenza (Healthy Volunteers)","enrollment":32},{"nctId":"NCT04544267","phase":"PHASE3","title":"Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-15","conditions":"Influenza","enrollment":100},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT07093281","phase":"PHASE4","title":"Intranasal LAIV Mucosal Immunity Examination","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-02","conditions":"Impact of Vaccination","enrollment":25},{"nctId":"NCT07240558","phase":"PHASE3","title":"Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-11-03","conditions":"Influenza (Pandemic), Avian Influenza, Vaccination","enrollment":120},{"nctId":"NCT07287137","phase":"PHASE4","title":"Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-11-12","conditions":"COVID -19, COVID - 19, COVID 19","enrollment":54},{"nctId":"NCT05569239","phase":"PHASE2","title":"Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg","status":"ACTIVE_NOT_RECRUITING","sponsor":"Osivax","startDate":"2025-09-08","conditions":"Influenza","enrollment":2850},{"nctId":"NCT06694025","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-10-01","conditions":"Immunization, Influenza (Healthy Volunteers)","enrollment":670},{"nctId":"NCT06855836","phase":"NA","title":"Motivational Interviewing to Increase Uptake of Drug Checking and Safe Drug Use Behaviors to Reduce Overdose","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-03-03","conditions":"Overdose","enrollment":588}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Influenza Fluzone vaccine","genericName":"Influenza Fluzone vaccine","companyName":"La Jolla Institute for Immunology","companyId":"la-jolla-institute-for-immunology","modality":"Biologic","firstApprovalDate":"","aiSummary":"Fluzone is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Prevention of seasonal influenza in adults and children ≥6 months of age.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}